Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 10 x ULN; for the purposes of this study, ULN for SGPT (ALT) is 45
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x the institutional ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x ULN
Alanine aminotransferase (ALT, serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN, must be obtained within 8 weeks prior to screening for protocol therapy
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN even in patients with documented hepatic involvement with lymphoma
Serum glutamate pyruvate aminotransferase (SGPT) alanine transferase (ALT) =< 2.5 x ULN, within 14 days of registration
Obtained within 14 days prior to registration: Serum glutamate pyruvate transaminase (SGPT) alanine aminotransferase (ALT) =< 2.5 x ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110 U/L
Alanine aminotransferase (AST) (serum glutamate pyruvate transaminase [SGPT]): 7-56 U/L
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x ULN
Within 14 days of randomization: Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 1.5 x ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110 U/L.
Within 28 days prior to treatment start: Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5 x ULN\r\n* Temozolomide should not be administered if total bilirubin is > 2.0 mg/dl or SGPT(ALT) > 2.5 x ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]): =< 5 x the ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]): =< 5 x the ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x ULN, or =< 5 x ULN in patients with documented liver metastases within 14 days of cycle 1 day 1
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110 U/L within 14 days of registration
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5 x ULN for age
Alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) < 2.5 x ULN
Alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 200
Alanine transferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 X ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 X institutional ULN
Aspartate transaminase (AST) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN unless evidence of the direct liver and/or bone involvement by lymphoma, then =< 5 x ULN, obtained =< 7 days prior to registration
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) concentration < 5 x the ULN; patients with metastatic liver disease are eligible if SGPT (ALT) is < 20 x the ULN
Alanine aminotransferase (ALT)/serum glutamic pyruvate transaminase (SGPT) =< 2.5 x ULN
For Part A participants: serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) concentration =< 5 x the institutional ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]): =< 5 x the ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2 x ULN
Alanine aminotransferase (ALT)/serum glutamate pyruvate transaminase (SGPT) =< 3 x UNL (=< 5x ULN if liver metastases present) obtained =< 2 weeks prior to enrollment
Alanine aminotransferase (ALT, serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x ULN for age
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 X ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x ULN for age
Alanine aminotransferase (ALT, serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN (=< 5.0 x ULN in patients with known liver metastases)
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 X institutional ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 X ULN
Within 7 days prior to study registration: Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 110 U/L
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2 x ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 X ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 4 x ULN for age, unless elevation due to leukemic infiltration
Serum glutamic pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 times institutional ULN for age
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x IULN except when in the opinion of treating physician is due to direct involvement of leukemia (e.g. hepatic infiltration or biliary obstruction due to leukemia) or Gilbert's disease
Alanine aminotransaminase (ALT, serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 X ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x ULN
Alanine aminotransferase (ALT, serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 200
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 200
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 x ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 X ULN; exception for patients with liver metastasis: ALT (SGPT) =< 5 X ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 x ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 x ULN
Alanine aminotransferase (ALT) =< 3 x ULN (serum glutamate pyruvate transaminase [SGPT])
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) concentration < 5 X the institutional ULN
Alanine aminotransferase (ALT, serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5 X ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 5 x ULN; in patients with significant liver disease and chronically elevated liver transaminases, ALT may be elevated as high as 8 x ULN
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x ULN for age
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 5 x normal
Alanine aminotransferase (ALT, serum glutamate pyruvate transaminase [SGPT]) =< 3 × ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 × institutional ULN
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional ULN obtained =< 45 days prior to randomization
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x ULN, obtained within 14 days prior to treatment start
Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases, performed within 10 days of treatment initiation
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x ULN
